These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 14999700)

  • 21. Efficacy of alpha-interferon therapy of chronic hepatitis patients infected with wild type hepatitis B virus and HBEAG-minus mutant.
    Husa P; Chalupa P; Stroblová H; Husová L; Slesinger P
    Acta Virol; 2001; 45(5-6):293-7. PubMed ID: 12083328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
    Lin SM; Yu ML; Lee CM; Chien RN; Sheen IS; Chu CM; Liaw YF
    J Hepatol; 2007 Jan; 46(1):45-52. PubMed ID: 17107734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R; Korevaar A; Lada O; Martinot-Peignoux M; Boyer N; Mackiewicz V; Dauvergne A; Cardoso AC; Asselah T; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The long-term course of chronic hepatitis B.
    Di Marco V; Lo Iacono O; Cammà C; Vaccaro A; Giunta M; Martorana G; Fuschi P; Almasio PL; Craxì A
    Hepatology; 1999 Jul; 30(1):257-64. PubMed ID: 10385664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
    J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
    Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
    Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece.
    Baltayiannis G; Katsanos K; Karayiannis P; Tsianos EV
    Aliment Pharmacol Ther; 2006 Aug; 24(3):525-33. PubMed ID: 16886919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
    van der Eijk AA; Niesters HG; Hansen BE; Heijtink RA; Janssen HL; Schalm SW; de Man RA
    J Viral Hepat; 2006 Feb; 13(2):96-103. PubMed ID: 16436127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Tangkijvanich P; Thong-ngam D; Mahachai V; Kladchareon N; Suwangool P; Kullavanijaya P
    Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):452-8. PubMed ID: 11944697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.
    Jonas MM; Little NR; Gardner SD;
    J Viral Hepat; 2008 Jan; 15(1):20-7. PubMed ID: 18088241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
    Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
    J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent progress and new trends in the treatment of hepatitis B.
    Alberti A; Brunetto MR; Colombo M; Craxì A
    J Med Virol; 2002 Jul; 67(3):458-62. PubMed ID: 12116046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission.
    Jang MK; Choi DR; Lee JY; Moon HK; Lee JH; Kim SM; Kim KH; Park JY; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Yoo JY
    J Infect; 2005 Nov; 51(4):314-7. PubMed ID: 16291284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter retrospective study of response to interferon in chronic hepatitis B.
    Martín-Vivaldi R; Nogueras F; Vignote ML; Salmerón J; Aguilar J; Romero M; Andrade R; De la Mata M; Moreno JM; Pérez J; García G; López de Hierro M; Gómez F; Palacios A; Otero S; Suárez E; Poyatos A; Quintero D
    Rev Esp Enferm Dig; 2000 Sep; 92(9):561-72. PubMed ID: 11138238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.